Ignet
v2.0 Sign In

Gene Information

Gene symbol: PALB2

Gene name: partner and localizer of BRCA2

HGNC ID: 26144

Synonyms: FLJ21816, FANCN

Related Genes

# Gene Symbol Number of hits
1 ATM 1 hits
2 BLM 1 hits
3 BRCA1 1 hits
4 BRCA2 1 hits
5 BRIP1 1 hits
6 CDH1 1 hits
7 CHEK2 1 hits
8 DCLRE1A 1 hits
9 ERCC1 1 hits
10 FANCA 1 hits
11 MLH3 1 hits
12 MSH2 1 hits
13 MSH6 1 hits
14 MUTYH 1 hits
15 NBN 1 hits
16 PARP1 1 hits
17 PTEN 1 hits
18 RAD50 1 hits
19 RAD51C 1 hits
20 RBM10 1 hits
21 TIPARP 1 hits
22 TP53 1 hits
23 XPA 1 hits

Related Sentences

# PMID Sentence
1 33426465 Patients (N=37 349) had RS results of whom 714 had <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, <i>ATM</i>, <i>PALB2</i>, or Lynch syndrome (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>) PVs.
2 33426465 For women aged 50 years or older at breast cancer diagnosis, RS often exceeded the chemotherapy benefit threshold (≥26) with <i>BRCA1</i> (71.7% vs 14.4% with none; <i>P</i> &lt;.001), <i>PALB2</i> (37.1%; <i>P</i> = .001), and <i>BRCA2</i> (44.3%; <i>P</i> &lt; .001) PVs.
3 33426465 PVs in <i>BRCA1</i>, but not <i>BRCA2</i>, <i>PALB2</i>, <i>ATM</i>, <i>CHEK2</i>, or Lynch syndrome genes, were associated with elevated RS on multivariable analysis (<i>P</i> &lt; .001).
4 33724863 We used panel sequencing containing 22 high/moderate-risk susceptibility genes and parallel MLPA analysis of BRCA1/2, CHEK2 genes, to analyze 94 individuals with a strong family/personal history of breast and/or ovarian cancer.
5 33724863 In total, we have identified 22 causal DNA variants (23.4%) showing 15 primary findings in BRCA1/2 genes (68.2%) and 7 positive secondary findings in CHEK2, PALB2, CDH1, and MUTYH genes (31.8%).
6 33724863 Besides known mutations, the BRCA1 variant c.2794del (p.Val932Leufs*68) and variant c.2480dup (p.Tyr827*) in the CDH1 gene represent the novel, previously unpublished variants that might be population-specific.
7 34606975 Hereditary breast and ovarian cancer (HBOC) is a syndrome defined by an increased risk of developing breast and/or ovarian cancer most commonly due to germline disease-causing variants in the BRCA1 and BRCA2 genes, but also other causative genes such as PALB2, ATM and CHEK2.
8 34933735 Also, MLH3 is a DNA mismatch repair gene and mutation in this gene is harmful in different cancers.
9 34933735 We identified 26 variants in breast cancer patients, 22 inherited variants were found in MLH3, CHECK2, BRCA1, BRCA2, BLM, TP53, MSH6, NBN and PTEN genes and 4 somatic variants were found in PALB2, RAD50 and RBM10 genes.
10 35293552 The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1.
11 35293552 The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1.
12 35293552 The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1.
13 35293552 The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively).
14 35293552 The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively).
15 35293552 The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively).
16 35293552 The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98).
17 35293552 The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98).
18 35293552 The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98).
19 35293552 The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients.
20 35293552 The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients.
21 35293552 The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients.
22 17292821 BRCA1 and BRCA2 mutations confer very high risks of breast and ovarian cancer. p53 and PTEN mutations lead to very high breast cancer risks associated with rare cancer syndromes.
23 17292821 BRCA1 and BRCA2 mutations confer very high risks of breast and ovarian cancer. p53 and PTEN mutations lead to very high breast cancer risks associated with rare cancer syndromes.
24 17292821 Mutations in CHEK2, ATM, NBS1, RAD50, BRIP1, and PALB2 are associated with doubling of breast cancer risks.
25 17292821 Mutations in CHEK2, ATM, NBS1, RAD50, BRIP1, and PALB2 are associated with doubling of breast cancer risks.
26 17292821 In addition, biallelic mutations in BRCA2, BRIP1, and PALB2 cause Fanconi anemia.
27 17292821 In addition, biallelic mutations in BRCA2, BRIP1, and PALB2 cause Fanconi anemia.
28 37851290 Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
29 38248108 Counselling Framework for Germline <i>BRCA1/2</i> and <i>PALB2</i> Carriers Considering Risk-Reducing Mastectomy.
30 38248108 Counselling Framework for Germline <i>BRCA1/2</i> and <i>PALB2</i> Carriers Considering Risk-Reducing Mastectomy.
31 38248108 Female <i>BRCA1/2</i> and <i>PALB2</i> germline pathogenic variant carriers have an increased lifetime risk of breast cancer and may wish to consider risk-reducing mastectomy (RRM) for surgical prevention.
32 38248108 Female <i>BRCA1/2</i> and <i>PALB2</i> germline pathogenic variant carriers have an increased lifetime risk of breast cancer and may wish to consider risk-reducing mastectomy (RRM) for surgical prevention.